Wuxi AppTec. 

WuXi AppTec Co., Ltd. functions as an investment holding entity, globally delivering a wide array of research, development, and manufacturing services. Operating across the People's Republic of China, other parts of Asia, the United States, and Europe, the company plays a crucial role in the discovery, advancement, and production of small molecule pharmaceuticals, as well as cell and gene therapies. The organization's operations are divided into six main segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Additional Services. It provides extensive contract research, development, and manufacturing organization (CRDMO) capabilities, supporting novel drug development from initial discovery phases through to commercial launch. This includes handling various synthetic molecular formats such as small molecules, oligonucleotides, peptides, and complex conjugates. Furthermore, WuXi AppTec offers biological services and solutions, spanning from target identification to candidate selection and progression into clinical trials, alongside integrated testing for drugs and medical devices from preclinical stages to clinical applications. The company also specializes in accelerating cell and gene therapies to market through an end-to-end solution, offers bespoke drug discovery services to pharmaceutical and biotech clients, and conducts clinical research. Founded in 2000, WuXi AppTec Co., Ltd. maintains its headquarters in Shanghai, People's Republic of China.